HOME >> MEDICINE >> NEWS
Medication shows modest benefit in reducing weight, improving HDL, triglyceride levels

Use of the weight-loss medication rimonabant produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels, according to a study in the February 15 issue of JAMA.

Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mellitus and cardiovascular disease and death from related causes. Researchers believe that besides weight loss, obesity management should target improvement in certain cardiometabolic risk factors, which include abnormal cholesterol and glucose (blood sugar) levels and excess weight around the waist, according to background information in the article. Long-term weight management remains a challenge for patients and clinicians.

F. Xavier Pi-Sunyer, M.D., of St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, and colleagues evaluated the efficacy and safety of the weight-loss medication rimonabant in conjunction with diet and exercise in promoting reductions in body weight and waist circumference, long-term weight maintenance, and reduction of cardiometabolic risk factors in obese and higher risk overweight patients. The randomized, double-blind, placebo-controlled study, conducted from August 2001 to April 2004, included 3,045 adults who were obese (body mass index 30 or greater) or overweight (body mass index greater than 27 and treated or untreated hypertension [high blood pressure] or dyslipidemia [abnormal levels of certain lipids and lipoproteins in the blood]). Patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were re-randomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2.

Year 1 of the study was completed by 51 percent of patients in the placebo group, 51 percent in the 5 mg of rimonabant
'"/>

Contact: Elizabeth Streich
212-305-6535
JAMA and Archives Journals
14-Feb-2006


Page: 1 2

Related medicine news :

1. Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
2. Medication errors affect childrens leukemia treatment
3. Medication may promote opening of arteries following stroke
4. IOM Advisory: Preventing Medication Errors News Conference on July 20
5. Medication use linked to farmers injuries
6. Medication plus oral contraceptive may improve female pattern hair loss
7. Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
8. Medications that lower blood pressure linked to reduced risk of Alzheimers disease
9. Medication plus beta-blocker helps prevent shocks from implantable cardioverter defibrillator
10. Medications and cough syrups may cause cavities
11. Medication reduces risk of heart irregularities after cardiac surgery

Post Your Comments:
(Date:2/26/2015)... 2015 marks five years of being ... Caggiano! , Orthodontics is a perfect blend of ... background in biomedical engineering, his artistic talent, his extensive ... dentist allows Dr. Caggiano to create innovative approaches to ... named Orthodontic Products’ Best of 2012, a national recognition, ...
(Date:2/26/2015)... The hip resurfacing procedure at Texas Orthopedics has ... Short to resume his active lifestyle, it has improved his ... Kilimanjaro, the highest free-standing mountain in the world, in an ... late 20s, Short suffered from early onset degeneration. His condition ... bone on bone. , Then about five years ago, ...
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 Beckman ... “Diversity of extracellular vesicles and their cargo in cell-to-cell ... vesicles and their relevance for cell-to-cell communication. The webinar ... March 4, 2015 at 8:00am PT. , Every cell ... extracellular vesicles (EVs) , often called “exosomes” or “microvesicles.” ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 2015 ... is a professional and in-depth study on the ... with a focus on the Chinese situation. ... are Lawton Gmbh & Co.KG, Hu-Friedy, Medisporex, Towne ... Instruments, Shuangyin, Shanghai Weirong Medical Equipment, Shuanglu, Changshu ...
(Date:2/26/2015)... 26, 2015 “ KnowNote ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... in rhythm and in tune. , Learning a musical instrument ... But what if people could take something they already know ...
Breaking Medicine News(10 mins):Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2
(Date:2/26/2015)... -- ABIVAX, a clinical stage biotech company developing ... it has dosed in New Zealand ... ABX203 which is taking place in several countries of the ... to assess whether ABX203 can deliver a significant improvement in ... load for a much longer period of time when compared ...
(Date:2/26/2015)... Medtronic, Inc. (U.S.), St. Jude Medical, ... in the Saudi Arabia , ... expected to lead the market during the period of 2014 ... player in the market, and owns a wide product portfolio ... Entera Neurostimulator are some of the most popular brands of ...
(Date:2/26/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter ended December 31, 2014, a 38% ... same period of 2013.  For the fiscal year 2014, ... increase compared to revenue of $207.9 million in 2013.  ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 2Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12
Cached News: